Understanding Colossal Biosciences’ Current Public Status
Colossal Biosciences is not currently a publicly traded company, meaning there is no active stock price, ticker symbol, or shares available for purchase on any stock exchange. Colossal Biosciences is a privately held biotechnology company specializing in genetic engineering and de-extinction research, with high-profile projects including efforts to bring back the woolly mammoth, dodo, and Tasmanian tiger (thylacine). As of 2025, the company has not completed an initial public offering (IPO) and its shares are not listed on the New York Stock Exchange (NYSE), Nasdaq, or any other major exchange.
This distinction is critical for investors seeking to understand how to potentially gain exposure to the company’s work. Unlike public companies that must file regular reports with the Securities and Exchange Commission (SEC), private companies like Colossal Biosciences operate under different disclosure requirements and investor access limitations.
Company Background and Mission
Colossal Biosciences was co-founded in 2021 by tech entrepreneur Ben Lamm and Harvard geneticist George Church, with the ambitious goal of reversing extinction through advanced CRISPR gene-editing technology. The company’s headquarters are located in Dallas, Texas, with research facilities in Boston and Miami.
The company’s primary research initiatives focus on three main de-extinction projects:
Woolly Mammoth Revival: Colossal Biosciences aims to create a cold-resistant elephant by editing genes from preserved woolly mammoth DNA. The company’s scientists have identified specific genetic traits that enabled mammoths to survive Arctic temperatures, including traits related to fat metabolism and hair growth.
Dodo Bird Restoration: The company is working to bring back the dodo, a flightless bird native to Mauritius that went extinct in the 17th century. This project involves analyzing the bird’s genome and identifying closest living relatives for genetic editing.
Tasmanian Tiger (Thylacine) Recovery: Colossal has announced plans to attempt reviving the thylacine, a marsupial predator that went extinct in 1936. The company has received significant funding specifically dedicated to this project.
Funding History and Valuation
Despite being private, Colossal Biosciences has attracted substantial investment from prominent venture capital firms and celebrity investors. The company has raised over $300 million across multiple funding rounds since its founding.
In February 2023, Colossal Biosciences announced a $150 million Series B funding round, which valued the company at approximately $1.5 billion, officially making it a “unicorn” startup valued at over $1 billion. This valuation was later revised upward in subsequent funding rounds.
The company’s notable investors include:
- Peter Thiel (via Founders Fund)
- Blake Nixon (billionaire investor)
- Tony Fadell (co-creator of iPod)
- Victor Vescovo (private investor)
- Climate Capital and other venture capital firms
This substantial funding demonstrates significant investor confidence in the company’s technology and mission, though it also means the company has been able to grow without access to public capital markets.
How to Invest in Colossal Biosciences
Since the company remains private, traditional methods of purchasing stock do not apply. However, there are several legal ways accredited investors may gain exposure:
Accredited Investor Status: The SEC restricts investment in private companies to “accredited investors” who meet specific income or net worth requirements. Individual investors can qualify by having either $200,000 in annual income (or $300,000 combined with a spouse), or a net worth exceeding $1 million excluding primary residence.
Direct Investment: Some private placement opportunities may be available through the company or participating investors. These are typically offered at significant minimums—often $25,000 or more—and carry substantial risk and limited liquidity.
Venture Capital Funds: Several venture capital funds have invested in Colossal Biosciences. Accredited investors may gain indirect exposure by investing in funds that include Colossal in their portfolios, though selection and due diligence remain essential.
Secondary Markets: Limited secondary market platforms occasionally facilitate trades of private company shares, though these arrangements are rare and carry legal complexity. Platforms like Notehub or EquityZen sometimes list shares from late-stage private companies.
Understanding Private Company Stock Risks
Investing in private biotechnology companies like Colossal Biosciences carries distinct risks that potential investors must carefully evaluate:
Illiquidity: Unlike publicly traded stocks, private company shares cannot be quickly sold. Investment lock-up periods often extend for years, and finding a buyer can be extremely difficult. Even when secondary markets exist, prices may be significantly discounted from any stated valuation.
Valuation Uncertainty: Private company valuations are often based on the most recent funding round, which may not reflect current market conditions. Unlike public companies with daily stock price updates, the true value of private holdings can only be determined during actual transactions.
Regulatory Limitations: Private companies face fewer disclosure requirements than public companies. Investors have limited access to financial information, operational data, and business risks compared to public company shareholders.
Dilution Risk: Private companies frequently issue new shares in funding rounds, which can decrease the percentage ownership and value of existing shares. Multiple funding rounds since founding have diluted early investor positions.
Business Risk: De-extinction technology remains largely unproven at commercial scale. Scientific challenges, regulatory hurdles, and competition could significantly impact the company’s long-term success.
Exit Uncertainty: Without an IPO or acquisition, investors may have no viable exit strategy for their investment. No public company has successfully commercialized de-extinction technology.
Comparing Public vs. Private Biotechnology Companies
For investors interested in the biotechnology sector, understanding the differences between public and private companies is essential:
| Factor | Public Biotech Companies | Private Companies (Colossal) |
|---|---|---|
| Stock Price | Daily market pricing | No established market price |
| Trading Access | Available to general public | Limited to accredited investors |
| Disclosure | SEC filings required | Selective disclosure |
| Liquidity | Highly liquid | Illiquid |
| Valuation | Market-determined | Last funding round |
| Shareholder Count | Unlimited | Limited to 500+ |
Public biotechnology companies with similar research focuses include companies working on gene editing, synthetic biology, and genetic therapeutics. These may offer more accessible investment opportunities with clearer pricing mechanisms.
The Potential IPO Path
While Colossal Biosciences has not announced specific IPO plans, industry analysts speculate the company may consider going public within the next several years if it achieves significant scientific milestones. Several biotechnology companies have pursued IPOs after demonstrating proof of concept in genetic engineering.
Indicators that might precede an IPO announcement include:
- Achievement of significant de-extinction milestones
- Establishment of commercial partnerships or revenue
- Completion of late-stage research that de-risks the technology
- Favorable regulatory developments for genetic engineering
- Improvement in overall market conditions for biotech IPOs
Investors interested in potential future public offerings can monitor SEC filings, news announcements, and the company’s official communications for updates on any IPO intentions.
Conclusion
Colossal Biosciences represents one of the most ambitious biotechnology ventures of the 21st century, pursuing the once-impossible goal of reversing extinction through genetic engineering. However, as a private company with no publicly traded shares, there is no live stock price, real-time chart data, or traditional investment mechanism available to general retail investors.
For those interested in gaining exposure to the company, options remain extremely limited and typically restricted to accredited investors through private placement opportunities or venture capital funds. The company has achieved significant valuation milestones, becoming one of the most well-funded private biotechnology companies, though de-extinction technology remains experimental with an uncertain commercial pathway.
Anyone considering investment should conduct thorough due diligence, understand the substantial risks of private company investment, and consult with financial advisors familiar with alternative investment opportunities in the biotechnology sector.
Frequently Asked Questions
Does Colossal Biosciences have a stock ticker symbol?
No, Colossal Biosciences does not have a stock ticker symbol. The company is privately held and has not completed an initial public offering (IPO). Shares are not traded on NYSE, Nasdaq, or any other stock exchange.
Can retail investors buy Colossal Biosciences stock?
General retail investors cannot purchase Colossal Biosciences stock. Only “accredited investors” who meet specific SEC requirements (income of $200,000+ annually or net worth exceeding $1 million) may qualify for certain private investment opportunities, though such opportunities are rare and carry significant risk.
What is Colossal Biosciences’ current valuation?
Colossal Biosciences achieved “unicorn” status with a valuation exceeding $1 billion following its Series B funding round in early 2023. Later funding rounds have reportedly increased this valuation, though precise current figures are not publicly disclosed as the company remains private.
When might Colossal Biosciences go public?
The company has not announced specific plans for an IPO. Industry speculation suggests the company may consider going public if it achieves significant scientific milestones, though timing remains entirely uncertain and no announcements have been made.
What are the main risks of investing in private biotech companies like Colossal?
Key risks include illiquidity (inability to sell shares quickly), limited disclosure and transparency, valuation uncertainty, potential dilution through future funding rounds, and significant business risk given the experimental nature of de-extinction technology. Investors should be prepared for the possibility of total loss of investment.